Efficacy and Safety of the Combination Nasal Spray Olopatadine Hydrochloride-Mometasone Furoate in the Treatment of allergic Rhinitis

Introduction: Pharmacotherapy is the mainstay in the treatment of allergic rhinitis. While antihistamines (AH) and intranasal glucocorticosteroids (INCS) have long been part of the therapeutic standard, a pharmacological combination of both active ingredients in a nasal spray has so far only been implemented and made available in two preparations in Germany. Recently, an intranasal olopatadine hydrochloride-mometasone furoate (Olo-Mom) combination was introduced as a nasal spray in the treatment of seasonal and perennial allergic rhinitis.<br /> Methods: In a literature search, treatment options for allergic rhinitis were analyzed and the available evidence was determined through research in Medline, PubMed as well as the national and international study (ClinicalTrials.gov) and guideline registers and the Cochrane Library. Human studies published on the topic up to and including 8/2023 were taken into account.<br /> Results: Based on the international literature and previous experience, the results are summarized and recommendations are given. The drugs used in the pharmacotherapy of AR primarily include INCS, intranasal and oral AH, leukotriene antagonists, intranasal cromoglycic acid preparations, intranasal and oral vasoconstrictors and nasal rinses. INCS are the first-line therapy for patients with intermittent and persistent allergic rhinitis, but in many patients they do not work sufficiently or do not work quickly enough. In two phase II clinical trials, the fixed combination Olo-Mom nasal spray showed significant improvements in the reflective total nasal symptom score (rTNSS) when administered twice daily and once daily. In Phase III studies, Olo-Mom nasal spray administered twice daily demonstrated significant improvements in rTNSS compared to placebo, olo-patadine monotherapy and mometasone monotherapy.